Neutralization of SARS-CoV-2 Omicron subvariant BA.2.87.1

/in

Lasrado N, Rössler A, Rowe M, Collier AY, Barouch DH. Neutralization of SARS-CoV-2 Omicron subvariant BA.2.87.1. Vaccine. 2024 Apr 2;42(9):2117-2121. doi: 10.1016/j.vaccine.2024.03.007. Epub 2024 Mar 7. PMID: 38458874.

Zeolitic imidazolate frameworks activate endosomal Toll-like receptors and potentiate immunogenicity of SARS-CoV-2 spike protein trimer

/in

Alsaiari SK, Nadeef S, Daristotle JL, Rothwell W, Du B, Garcia J, Zhang L, Sarmadi M, Forster TA, Menon N, Lin SQ, Tostanoski LH, Hachmann N, Wang EY, Ventura JD, Barouch DH, Langer R, Jaklenec A. Zeolitic imidazolate frameworks activate endosomal Toll-like receptors and potentiate immunogenicity of SARS-CoV-2 spike protein trimer. Sci Adv. 2024 Mar 8;10(10):eadj6380. doi: 10.1126/sciadv.adj6380. Epub 2024 Mar 6. PMID: 38446889; PMCID: PMC10917347.

Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV

/in ,

Mayer BT, Zhang L, deCamp AC, Yu C, Sato A, Angier H, Seaton KE, Yates N, Ledgerwood JE, Mayer K, et al. Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV. Pharmaceutics. 2024; 16(5):594. https://doi.org/10.3390/pharmaceutics16050594

High Frequency of Prior Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Sensitive Nucleocapsid Assays

/in ,

Joseph P Nkolola, Jinyan Liu, Ai-ris Y Collier, Catherine Jacob-Dolan, Yasmeen Senussi, Ella Borberg, Zoe Swank, David R Walt, Dan H Barouch, High Frequency of Prior Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Sensitive Nucleocapsid Assays, The Journal of Infectious Diseases, 2024;, jiae174, https://doi.org/10.1093/infdis/jiae174

Neutralization of SARS-CoV-2 Omicron subvariant BA.2.87.1

/in ,

Lasrado N, Rössler A, Rowe M, Collier AY, Barouch DH. Neutralization of SARS-CoV-2 Omicron subvariant BA.2.87.1. Vaccine. 2024 Apr 2;42(9):2117-2121. doi: 10.1016/j.vaccine.2024.03.007. Epub 2024 Mar 7. PMID: 38458874.

Modeling resistance to the broadly neutralizing antibody PGT121 in people living with HIV-1

/in ,

Cassidy T, Stephenson KE, Barouch DH, Perelson AS (2024) Modeling resistance to the broadly neutralizing antibody PGT121 in people living with HIV-1. PLOS Computational Biology 20(3): e1011518. https://doi.org/10.1371/journal.pcbi.1011518

Comparison of the immunogenicity and protective efficacy of ACAM2000, MVA, and vectored subunit vaccines for Mpox in rhesus macaques

/in

Jacob-Dolan C, Ty D, Hope D, McMahan K, Liu J, Powers OC, Cotter CA, Sciacca M, Wu C, Borducchi E, Bouffard E, Richter H, Velasco J, Teow E, Boursiquot M, Cook A, Feliciano K, Yalley-Ogunro J, Seaman MS, Pessiant L, Lewis MG, Andersen H, Moss B, Barouch DH. Comparison of the immunogenicity and protective efficacy of ACAM2000, MVA, and vectored subunit vaccines for Mpox in rhesus macaques. Sci Transl Med. 2024 Mar 27;16(740):eadl4317. doi: 10.1126/scitranslmed.adl4317. Epub 2024 Mar 27. PMID: 38536937.

Waning immunity and IgG4 responses following bivalent mRNA boosting

/in

Lasrado N, Collier AY, Miller J, Hachmann NP, Liu J, Anand T, A Bondzie E, Fisher JL, Mazurek CR, Patio RC, Rodrigues SL, Rowe M, Surve N, Ty DM, Wu C, Chicz TM, Tong X, Korber B, McNamara RP, Barouch DH. Waning immunity and IgG4 responses following bivalent mRNA boosting. Sci Adv. 2024 Feb 23;10(8):eadj9945. doi: 10.1126/sciadv.adj9945. Epub 2024 Feb 23. PMID: 38394195; PMCID: PMC10889350.

mRNA vaccines against SARS-CoV-2 induce divergent antigen-specific T-cell responses in patients with lung cancer

/in ,
Song NJ, Chakravarthy KB, Jeon H, Bolyard C, Reynolds K, Weller KP, Reisinger S, Wang Y, Li A, Jiang S, Ma Q, Barouch DH, Rubinstein MP, Shields PG, Oltz EM, Chung D, Li Z. mRNA vaccines against SARS-CoV-2 induce divergent antigen-specific T-cell responses in patients with lung cancer. J Immunother Cancer. 2024 Jan 4;12(1):e007922. doi: 10.1136/jitc-2023-007922. PMID: 38177076; PMCID: PMC10773442.

Prophylactic HIV-1 vaccine trials: past, present, and future

/in

Nkolola JP, Barouch DH. Prophylactic HIV-1 vaccine trials: past, present, and future. Lancet HIV. 2023 Dec 20:S2352-3018(23)00264-3. doi: 10.1016/S2352-3018(23)00264-3. Epub ahead of print. PMID: 38141639.